Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

被引：0

作者：

Li, Shuluan ^{[1
,2
]}

Zhang, Pei ^{[3
]}

Wang, Tianyu ^{[2
,4
]}

Wang, Jie ^{[3
]}

Duan, Jianchun ^{[3
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol Natl,Canc Ctr, Shenzhen 100021, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing 100021, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Dept Breast Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Shenzhen, Peoples R China

来源：

THORACIC CANCER | 2021年 / 12卷 / 23期

关键词：

ALK; brigatinib; chemotherapy; lung squamous cell carcinoma; 1ST-LINE CRIZOTINIB; OPEN-LABEL; CANCER; ROS1;

D O I：

10.1111/1759-7714.14133

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK-positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK-positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first-line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor.

引用

页码：3273 / 3276

页数：4

共 50 条

[21] A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations
Alrifai, Doraid
Popat, Sanjay
Ahmed, Merina
Gonzalez, David
Nicholson, Andrew G.
du Parcq, John
Benepal, Tim
LUNG CANCER, 2013, 80 (03) : 339 - 340
[22] Synchronous primary lung sarcomatous carcinoma and lung squamous cell carcinoma: a case report
Zhao, Maoyuan
Jing, Qiuyang
Hui, Zhouguang
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (03): : 480 - 483
[23] Squamous cell carcinoma with lung metastasis in equine: Case report
Gueiros Silva, Stephanie Caroline
Ferreira Alves, Amanda de Deus
Ronnau, Milton
Araujo de Medeiros Torres, Marcia Bersane
BRAZILIAN JOURNAL OF HYGIENE AND ANIMAL SANITY, 2015, 9 (03): : 543 - 552
[24] Squamous cell carcinoma with lung metastasis in equine: Case report
Gueiros Silva, Stephanie Caroline
Ferreira Alves, Amanda de Deus
Ronnau, Milton
Araujo de Medeiros Torres, Marcia Bersane
BRAZILIAN JOURNAL OF HYGIENE AND ANIMAL SANITY, 2015, 9 (04): : 689 - 698
[25] Infliximab/methotrexateRecurrence of lung squamous cell carcinoma: case report
Reactions Weekly, 2022, 1929 (1) : 351 - 351
[26] BENEFITS OF ALECTINIB AS FIRST-LINE TREATMENT OF ALK-MUTATED LUNG SQUAMOUS CELL CARCINOMA: A CASE REPORT
HE, S. H. E. N. L. I. N. G.
ZENG, A. I. P. I. N. G.
ACTA MEDICA MEDITERRANEA, 2022, 38 (01): : 337 - 339
[27] Therapeutic effects of an ALK inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion
Suetsugu, Takayuki
Masada, Yutaka
Kozono, Tomoki
Morita, Kahoru
Yonezawa, Hajime
Tabata, Kazuhiro
Seki, Naohiko
Mizuno, Keiko
Tanaka, Kentaro
Inoue, Hiromasa
RESPIRATORY INVESTIGATION, 2024, 62 (06) : 1157 - 1160
[28] One case of Recurrent Lung Squamous Cell Carcinoma Treated with Toripalimab
Liu, Bing
Sui, Yan
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 127 : 164 - 164
[29] Synchronous lung cancer presenting with small cell carcinoma and squamous cell lung carcinoma: a case report
Stirpe, Emanuele
Bardaro, Floriana
Archives, Monaldi
MONALDI ARCHIVES FOR CHEST DISEASE, 2024, 94 (03)
[30] Non keratinizing squamous cell lung carcinoma mimics small cell carcinoma in the lung: A case report
Laila, Surmita
Arliny, Yunita
Kurniawan, Ferry Dwi
Kamarlis, Reno Keumalazia
RESPIROLOGY, 2023, 28 : 283 - 284

← 1 2 3 4 5 →